1. Regulatory mechanisms and therapeutic potential of microglial inhibitors in neuropathic pain and morphine tolerance
Journal of Zhejiang University. Science. B 2020;21(3):204-217
Microglia are important cells involved in the regulation of neuropathic pain (NPP) and morphine tolerance. Information on their plasticity and polarity has been elucidated after determining their physiological structure, but there is still much to learn about the role of this type of cell in NPP and morphine tolerance. Microglia mediate multiple functions in health and disease by controlling damage in the central nervous system (CNS) and endogenous immune responses to disease. Microglial activation can result in altered opioid system activity, and NPP is characterized by resistance to morphine. Here we investigate the regulatory mechanisms of microglia and review the potential of microglial inhibitors for modulating NPP and morphine tolerance. Targeted inhibition of glial activation is a clinically promising approach to the treatment of NPP and the prevention of morphine tolerance. Finally, we suggest directions for future research on microglial inhibitors.
2.Inhibition of proliferation in Jurkat cells transfected with exogenous HCAP1 gene.
Xiang-Hua WU ; Rong WANG ; Jun-Xiang DU ; Qi-Tian MU ; Lie-Ping GUO ; Pei-Er ZHEN ; Da-Fang WAN ; Jian-Ren GU
Journal of Experimental Hematology 2003;11(5):454-457
HCAP1 is a novel hepatic cancer related gene located on human chromosome 17p13.3. The loss of heterozygosity occurred at 17p13.3 in various human cancers. In order to investigate the effects of exogenous HCAP1 gene products on cell proliferation of T lymphoma Jurkat cell line, HCAP1 gene! was transfected into Jurkat cells mediated by liposome, and the cells stably expressing exogenous HCAP1 were screened with G418. The effects of HCAP1 products on cell proliferation were assessed by viable cell count, cell growth curve and colony formation assay in soft agar. The results showed that the HCAP1 transgenic Jurkat cells displayed slow growth rate, extended doubling time and reduced colony formation capability, as compared with the cells transfected with pBK/CMV empty vector (P < 0.01). It is concluded that exogenous HCAP1 gene products could inhibit the proliferation of Jurkat cells.
Carcinoma, Hepatocellular
;
genetics
;
Cell Division
;
Humans
;
Jurkat Cells
;
Liver Neoplasms
;
genetics
;
Neoplasm Proteins
;
genetics
;
Peptides
;
Transfection
3.Expression of survivin, Fas, bcl-2 and bax in bone marrow cells from acute myeloid leukemia patients and its clinical significance.
Feng-Ru LIN ; Ying WANG ; Rong-Qi WANG ; Xing-Yan DU ; Xiao-Nan GUO ; Jin-Hai REN ; Xiao-Ling GUO ; Li YAO ; Er-Gu YAO
Journal of Experimental Hematology 2003;11(3):259-262
UNLABELLEDTo study the clinical significance of the expression of antiapoptosis gene, survivin and bcl-2, and proapoptosis gene, Fas and bax, in acute myeloid leukemia (AML), RT-PCR was used to examine the expression of survivin and flow cytometry (FCM) to detect the expression of Fas, bcl-2, bax and bcl-2/bax ratio in 68 cases of AML. The results demonstrated that: (1) The positivity of survivin mRNA expression was significantly higher in AML compared to control (70.6% vs 30%, P < 0.05). (2) The expression of Fas and bcl-2 in AML before treatment was significantly higher than that in control (P < 0.001), but the bax expression did not (P > 0.05). (3) The survivin-positive AML cases showed a significantly lower Fas and higher bcl-2 expression in comparison with survivin-negative ones (P < 0.01 and P < 0.001, respectively), but the bax did not (P > 0.01). (4) Survivin-positive AML cases had a lower CR rate as compared with survivin-negative cases (64.6% vs 90%, P < 0.05). (5) The survivin-positive CR cases showed a decreased expression of Fas and bcl-2 after treatment in comparison with pretreatment expression (P < 0.001), but the bax expression remained unchanged before and after therapy. The survivin-positive NR cases showed a significantly decreased Fas and increased bcl-2 expression as compared with pretreatment expression (P < 0.001). bcl-2/bax ratio was also significantly higher in NR cases.
IN CONCLUSION70.6% AML cases showed positive for survivin expression with a lower CR rate, the survivin-positive AML showed a low Fas with high bcl-2 expression and bcl-2/bax ratio as compared to the survivin-negative cases.
Adolescent ; Adult ; Aged ; Antineoplastic Agents ; therapeutic use ; Biomarkers, Tumor ; biosynthesis ; genetics ; Bone Marrow Cells ; drug effects ; metabolism ; Female ; Flow Cytometry ; Gene Expression Regulation, Neoplastic ; Humans ; Inhibitor of Apoptosis Proteins ; Leukemia, Myeloid, Acute ; drug therapy ; genetics ; metabolism ; Male ; Microtubule-Associated Proteins ; genetics ; Middle Aged ; Neoplasm Proteins ; Proto-Oncogene Proteins ; biosynthesis ; Proto-Oncogene Proteins c-bcl-2 ; biosynthesis ; RNA, Messenger ; drug effects ; genetics ; metabolism ; bcl-2-Associated X Protein ; fas Receptor ; biosynthesis
4.Differentiation of bone marrow derived from mesenchymal stem cells into cardiomyocyte-like cells induced by co-culture with rat myocardial cells.
Rong-Li ZHANG ; Er-Lie JIANG ; Mei WANG ; Zheng ZHOU ; Wen-Jing ZHAI ; Wei-Hua ZHAI ; Hua WANG ; Zhi-Yong WANG ; Yu-Shi BAO ; Hong DU ; Ming-Zhe HAN
Journal of Experimental Hematology 2008;16(5):1111-1115
The study was purposed to investigate the differentiation ability of mesenchymal stem cells (MSCs) into myocardial cells in vitro. Rat bone marrow-derived MSCs were labeled and co-cultured with neonatal rat cardiomyocytes (CM) for 5 - 7 days. The expression of cell surface antigens was detected by flow cytometry, and the expression of muscle-specific marker myosin and troponin T in labeled cells was detected by immunofluorescence. The results showed that in vitro cultured MSCs expressed CD90, CD44, CD105, CD54, not expressed CD34, CD45, CD31. After co-cultured with neonatal rat CM, labeled MSCs differentiated into cardiomyocyte-like cells expressing myosin and troponin T. It is concluded that MSCs can differentiate into cardiomyocyte-like cells when co-cultured with neonatal myocardial cells in vitro. In co-culture of two kind of cells in ratio of four to one showed obvious efficacy differentiating MSCs into CMs.
Animals
;
Bone Marrow Cells
;
cytology
;
Cell Differentiation
;
Cells, Cultured
;
Coculture Techniques
;
Mesenchymal Stromal Cells
;
cytology
;
Myocytes, Cardiac
;
cytology
;
Rats
;
Rats, Wistar
5.Prognosis and related factors of acute lymphoblastic leukemia.
Wei ZHANG ; Rong FU ; Wen-Hui LIU ; Yu-Qian CHENG ; Wen-Xiu SONG ; Li-Juan DU ; Er-Bao RUAN ; Li-Tong ZHANG ; Xiao-Ming WANG ; Yong LIANG ; Guo-Jin WANG ; Wen QU ; Jia SONG ; Rong-Li ZHANG ; Jing GUAN ; Li-Juan LI ; Peng ZOU ; Zong-Hong SHAO
Journal of Experimental Hematology 2007;15(5):1102-1106
In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study. The therapeutic efficacy and prognosis of 53 cases of ALL were analyzed, the remission, relapse, overall survival and event-free survival were studied, and relation between different factors and prognosis of ALL were investigated by comparison of cases in same stage. The results showed that the complete remission was achieved in 36 out of 53 patients, the total remission rate was 67.9%, the total relapse rate was 37.7%, the median relapse duration was 6 months after remission. Median overall survival (OS) and median event-free survival (EFS) time were 4 and 1 months after remission respectively, OS and EFS rate of 18 month was 35.1% and 14.2%. The patients with different gender had significantly different EFS. Age was an independent risk factor of CR rate. White blood cell count and hemoglobin level of newly diagnosed patients were significantly correlated with OS and EFS. Absolute neutrophil count (ANC) at the end of the induction chemotherapy was an independent related factor of OS, the higher ANC, the lower risk of death. The patients with or without chemotherapy related infection had different relapse rate. The patients with bleeding after chemotherapy had lower OS when compared with those without bleeding. Serum glucose level was a significant negative prognostic factor. It is concluded that there is higher relapse rate, poor prognosis in adult ALL in comparison with children. In order to decrease the relapse rate and prolong the EFS, individual therapeutical regimens and prophylaxis of complicating diseases should be applied to ALL patients.
Adolescent
;
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Child
;
Female
;
Humans
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
prevention & control
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
diagnosis
;
therapy
;
Prognosis
;
Young Adult
6.Regulatory mechanisms and therapeutic potential of microglial inhibitors in neuropathic pain and morphine tolerance.
Er-Rong DU ; Rong-Ping FAN ; Li-Lou RONG ; Zhen XIE ; Chang-Shui XU
Journal of Zhejiang University. Science. B 2020;21(3):204-217
Microglia are important cells involved in the regulation of neuropathic pain (NPP) and morphine tolerance. Information on their plasticity and polarity has been elucidated after determining their physiological structure, but there is still much to learn about the role of this type of cell in NPP and morphine tolerance. Microglia mediate multiple functions in health and disease by controlling damage in the central nervous system (CNS) and endogenous immune responses to disease. Microglial activation can result in altered opioid system activity, and NPP is characterized by resistance to morphine. Here we investigate the regulatory mechanisms of microglia and review the potential of microglial inhibitors for modulating NPP and morphine tolerance. Targeted inhibition of glial activation is a clinically promising approach to the treatment of NPP and the prevention of morphine tolerance. Finally, we suggest directions for future research on microglial inhibitors.
Humans
;
Calcitonin Gene-Related Peptide/antagonists & inhibitors*
;
Drug Tolerance
;
Hypoglycemic Agents/pharmacology*
;
Microglia/physiology*
;
MicroRNAs/physiology*
;
Minocycline/pharmacology*
;
Morphine/pharmacology*
;
Neuralgia/etiology*
;
Plant Extracts/pharmacology*
;
Signal Transduction/physiology*
7.Ameliorative effect of rat bone marrow mesenchymal stem cell transplantation on infracted heart function.
Rong-Li ZHANG ; Er-Lie JIANG ; Mei WANG ; Zheng ZHOU ; Wen-Jing ZHAI ; Wei-Hua ZHAI ; Hua WANG ; Zhi-Yong WANG ; Yu-Shi BAO ; Hong DU ; Ming-Zhe HAN
Journal of Experimental Hematology 2009;17(2):390-394
This study was purposed to investigate the effects of rat marrow mesenchymal stem cell (rMSC) transplantation on left ventricular (LV) function in a rat myocardial infarction model. Myocardial infarction was performed in male Lewis rats by ligating the proximal left coronary artery. Rats were randomly divided into 3 groups: sham operation group (only thoracotomy, n = 8), AMI group (DF12 injection, n = 10), rMSC group (Dil-Labeled rMSC transplantation). At 8 weeks later, the cardiac functions including left ventricular ejection fraction (LVEF), left ventricular end systolic pressure (LVESP), left ventricular end diastolic pressure (LVEDP), +dp/dtmax and -dp/dtmax were evaluated by echocardiography and cardiac catheterization. The presence and differentiation of engrafted cells were assessed. CD31 was detected by immunohistochemical staining to demonstrate neovascular formation. The results indicated that the cultured in vitro rMSC expressed CD90, CD44, CD105, CD54; did not express CD34, CD45, CD31, as compared with AMI group, rMSC group showed a significant increase of LVEF, LVESP, +dp/dtmax, -dp/dtmax and a significant decrease of LVEDP. Immunofluorescence demonstrated that some transplanted rMSCs were positive for myosin, suggesting that small number of transplanted rMSCs differentiated into cardiac-like cells. Immunostaining showed marked augmentation of capillary density in the rMSC group than that of AMI group. It is concluded that transplanted rMSCs can differentiate into cardiac-like cells and rMSC transplantation can improve LV function after myocardial infarction in rats.
Animals
;
Bone Marrow Transplantation
;
Male
;
Mesenchymal Stem Cell Transplantation
;
Myocardial Infarction
;
physiopathology
;
surgery
;
Rats
;
Rats, Inbred Lew
;
Ventricular Function, Left
8.Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation.
Ben Fa GONG ; Ye Hui TAN ; Ai Jun LIAO ; Jian LI ; Yue Ying MAO ; Ning LU ; Yi DING ; Er Lie JIANG ; Tie Jun GONG ; Zhi Lin JIA ; Yu SUN ; Bing Zong LI ; Shu Chuan LIU ; Juan DU ; Wen Rong HUANG ; Hui WEI ; Jian Xiang WANG
Chinese Journal of Hematology 2018;39(6):460-464
Objective: To evaluate the impact of KIT D816 mutation on the salvage therapy in relapsed acute myeloid leukemia (AML) with t(8;21) translocation. Method: The characteristics of the first relapsed AML with t(8;21) translocation from 10 hospitals were retrospectively collected, complete remission (CR(2)) rate after one course salvage chemotherapy and the relationship between KIT mutation and CR(2) rate was analyzed. Results: 68 cases were enrolled in this study, and 30 cases (44.1%) achieved CR(2). All patients received KIT mutation detection, and KIT D816 mutation was identified in 26 cases. The KIT D816 positive group had significantly lower CR(2) compared with non-KIT D816 group (23.1% vs 57.1%, χ(2)=7.559, P=0.006), and patients with longer CR(1) duration achieved significantly higher CR(2) than those with CR(1) duration less than 12 months (74.1% vs 31.9%, χ(2)=9.192, P=0.002). KIT D816 mutation was tightly related to shorter CR(1) duration. No significant difference of 2 years post relapse survival was observed between KIT D816 mutation and non-KIT D816 mutation group. Conclusion: KIT D816 mutation at diagnosis was an adverse factor on the salvage therapy in relapsed AML with t(8;21) translocation, significantly related to shorter CR1 duration, and can be used for prediction of salvage therapy response. KIT D816 mutation could guide the decision-making of salvage therapy in relapsed AML with t(8;21) translocation.
Antineoplastic Combined Chemotherapy Protocols
;
Cytarabine
;
Humans
;
Leukemia, Myeloid, Acute/therapy*
;
Prognosis
;
Retrospective Studies
;
Salvage Therapy
9.Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia.
Chun-Yan LIU ; Rong FU ; Wen-Hui LIU ; Yu-Qian CHENG ; Wen-Xiu SONG ; Li-Juan DU ; Er-Bao RUAN ; Li-Tong ZHANG ; Xiao-Ming WANG ; Yong LIANG ; Guo-Jin WANG ; Wen QU ; Jia SONG ; Rong-Li ZHANG ; Jing GUAN ; Li-Juan LI ; Yang SONG ; Shan GAO ; Hui LIU ; Hui-Juan JIANG ; Jun WANG ; Peng ZOU ; Zong-Hong SHAO
Journal of Experimental Hematology 2007;15(6):1300-1304
To analyze the prognosis and risk factors of acute nonlymphocytic leukemia (ANLL), 94 patients with acute nonlymphocytic leukemia were enrolled in this study, while survival rate and risk factors of prognosis were analyzed. The results indicated that the complete remission (CR) ratio was 51.1%. Overall survival and event-free survival rates of month 6, 12, 18, 24 were 68.6%, 55.8%, 53.8%, 46.4%, 21.3% and 57.9%, 38.6%, 33.3%, 31.6%, 0% respectively. The factors such as age<40 years, WBC<10.0x10(9)/L before chemotherapy, WBC in the period of bone marrow suppression<1.0x10(9)/L, chemotherapy within 1 month after occurrence of leukemia, blood transfusion before chemotherapy of APL had favourable influence on remission and survival rates of ANLL patients. CR1, the time to get CR, length of CR and relapse significantly correlated with prognosis (p<0.05). It is concluded that the individualized therapy concerning the risk factors should be applied to ANLL patients for improving the remission, survival rate and prognosis.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Cytarabine
;
administration & dosage
;
therapeutic use
;
Female
;
Harringtonines
;
administration & dosage
;
therapeutic use
;
Humans
;
Leukemia, Myeloid, Acute
;
diagnosis
;
drug therapy
;
Male
;
Middle Aged
;
Prognosis
;
Tretinoin
;
administration & dosage
;
therapeutic use
;
Young Adult
10.Isolation and structural identification of a potassium ion channel Kv4.1 inhibitor SsTx-P2 from centipede venom.
Canwei DU ; Fuchu YUAN ; Xinyi DUAN ; Mingqiang RONG ; Er MENG ; Changjun LIU
Journal of Zhejiang University. Medical sciences 2024;():1-7
OBJECTIVES:
To isolate potassium ion channel Kv4.1 inhibitor from centipede venom, and to determine its primary and spatial structure.
METHODS:
Ion-exchange chromatography and reversed-phase high-performance liquid chromatography were performed to separate and purify peptide components of centipede venom, and their inhibiting effect on Kv4.1 channel was determined by whole-cell patch clamp recording. The molecular weight of isolated peptide Kv4.1 channel inhibitor was identified with MALDI-TOF, its primary sequence was determined by Edman degradation sequencing and two-dimensional mass spectrometry, its patial structure was established based on iterative thread assembly refinement online analysis.
RESULTS:
A peptide SsTx-P2 was separated from centipede venom with the molecular weight of 6122.8, and its primary sequence consists of 53 amino acid residues, showed as NH2-ELTWDFVRTCCKLFPDKSECTKACATEFTGGDESRLKDVWPRKLRSGDSRLKD-OH. Peptide SsTx-P2 potently inhibited the current of Kv4.1 channel transiently transfected in HEK293 cell, with 1.0 μmol/L SsTx-P2 suppressing 95% current of Kv4.1 channel. Its spatial structure showed that SsTx-P2 shared a conserved helical structure.
CONCLUSIONS
The study has isolated a novel peptide SsTx-P2 from centipede venom, which can potently inhibit the potassium ion channel Kv4.1, and its spatial structure displays a certain degree of conservation.